COMMUNIQUÉS West-GlobeNewswire

Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
28/10/2026
FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial [...]
Curabotics Enters National Contract with Capstone Health Alliance, Bringing Robotics and Automation to Hundreds of Hospitals
28/10/2026
Unique agreement gives Capstone's member network direct access to Curabotics' proven automation solutions JACKSONVILLE, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Curabotics , a healthcare technology company dedicated to [...]
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
28/10/2026
– Patent provides coverage into 2043 for key aspects of how Symvess is manufactured, sterilized, stored and shipped. DURHAM, N.C., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage [...]
ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences
28/10/2026
ProQR to present its ADAR-mediated RNA editing approach and progress toward next-generation editing oligonucleotides at TIDES Europe plenary session AX-0810 Phase 1 data to be featured in two poster presentations at [...]
BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026
28/10/2026
BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental [...]
MaxCyte to Participate in Three Upcoming Investor Conferences
28/10/2026
ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of [...]
Spectral AI Schedules 2026 Third Quarter Financial Results and Conference Call
28/10/2026
DALLAS, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree® for ‘Ms. Represented’ Campaign
28/10/2026
The ‘Ms. Represented’ campaign expands its reach with professional snowboarder Chloe Kim, who shares her ADHD experience to help connect with a younger generation of women. More than 60% of U.S. women who reported ever [...]
60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome
28/10/2026
Company plans to explore botanical approval pathways before initiating a prescription drug development program WASHINGTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “ [...]
Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients
28/10/2026
Human Research Ethics Submission Deadline Nov ‘26 with Site Initiation Activities Followed by First Patient Screening Planned for Feb ‘27 MELBOURNE, Australia, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ( [...]
Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
28/10/2026
IRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026. Ms. Clase has [...]
RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
28/10/2026
MOUNTAIN VIEW, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and commercializing [...]
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
28/10/2026
PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability 29 of 30 planned U.S. [...]
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
28/10/2026
- Reaching the Pre-Specified 80 th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial - - Company to Report Topline Primary Endpoint Results this Quarter - NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- SELLAS [...]
Cannabix Technologies Evaluating Expansion into Breath-Based Health and Biomarker Market with Proprietary BCU “VOC” Platform
28/10/2026
VANCOUVER, British Columbia, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”), a developer of marijuana and alcohol breath testing [...]
Avaí Bio and Austrianova Announce Publication in Frontiers in Aging Journal Highlighting Novel Cell Encapsulation-Based Approach to Sustained Klotho Delivery
28/10/2026
LAS VEGAS, NV, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related disorders, and anti- [...]
Daré Bioscience Addresses New National Focus on Women’s Health in Virtual Investor “What This Means” Discussion
28/10/2026
Sabrina Martucci Johnson, President and CEO, shares her perspective on the recent White House Executive Order and how Daré Bioscience’s growing commercial portfolio and clinical pipeline position the Company to address [...]
Actinogen pivotal Alzheimer’s disease trial database lock milestone - topline results on track for mid-November
28/10/2026
New academic publication highlights the strong science behind oral Xanamem's brain cortisol-control mechanism SYDNEY, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that following [...]
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026
28/10/2026
MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026 [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum